Author

C. P. Vellano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

J. R. Marszalek· 2 shared A. A. Machado· 1 shared A. Boletta· 1 shared A. Jeschko· 1 shared A. Sorokin· 1 shared A. Verrecchia· 1 shared B. Amati· 1 shared C. A. Bristow· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. R. Marszalek

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance

V. Thatikonda, H. Lu, S. Jurado, K. Kostyrko, C. A. Bristow, K. Bosch, N. Feng, S. Gao, D. Gerlach, M. Gerlach, S. Lieb, A. Jeschko, A. A. Machado, E. D. Marszalek, M. Mahendra, , M. H. Hofmann

This study shows that combining KRASG12C and SOS1 inhibitors improves anti-tumor response and delays resistance in KRASG12C-driven cancers.

bioRxiv · Jan 23, 2023Cancer Biology

Targeting mitochondrial respiration and the BCL2 family in MYC-associated B-cell lymphoma

G. Donati, M. Rava, M. Filipuzzi, P. Nicoli, L. Cassina, A. Verrecchia, M. Doni, S. Rodighiero, F. Parodi, A. Boletta, C. P. Vellano, J. R. Marszalek, G. Draetta, B. Amati

This paper identifies OxPhos as a key MYC-driven process in DLBCL and shows that targeting ETC complex I with IACS-010759 synergizes with BCL2 inhibitors to kill lymphoma cells.

bioRxiv · Nov 22, 2020Cancer Biology